Previous 10 | Next 10 |
The following slide deck was published by FibroGen, Inc. in conjunction with this event. For further details see: FibroGen (FGEN) Investor Presentation
Image source: The Motley Fool. FibroGen, inc (NASDAQ: FGEN) Q3 2021 Earnings Call Nov 9, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: FibroGen, inc (FGEN) Q3 2021 Earnings Call Transcript
The following slide deck was published by FibroGen, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: FibroGen, Inc. 2021 Q3 - Results - Earnings Call Presentation
FibroGen, Inc. (FGEN) Q3 2021 Earnings Conference Call Nov 09, 2021 05:00 PM AM ET Company Participants Michael Tung - VP, Corporate Strategy and IR Enrique Conterno - CEO Juan Graham - CFO Mark Eisner - CMO John Hunter - CSO Conference Call Participants Annabel Samimy - Stifel Edwin Zhang - ...
FibroGen (NASDAQ:FGEN): Q3 GAAP EPS of $0.54 beats by $0.33. Revenue of $155.97M (+254.2% Y/Y) beats by $28.42M. Press Release The company expects 2021 ending balance of cash, cash equivalents, investments, and accounts receivable to be in the range of $580M-610M. For further details see: ...
Roxadustat Receives EU approval for Patients with Anemia of CKD , triggering a $120M milestone payment from Astellas Roxadustat net product revenue in China of $13.4 million, on a US GAAP basis. Total roxadustat net sales in China of $57.8 million 1 by ...
SAN FRANCISCO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2021 financial results on Tuesday, November 9 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment co...
SAN FRANCISCO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced that analyses from the global Phase 3 roxadustat clinical program will be presented at the American Society of Nephrology Kidney Week 2021 taking place virtually November 4 - 7, 2021. A total of ...
Gainers: ZBRA +7.0%. FGEN +5.0%. GOGO +4.0%. APLS +2.9%. MREO +2.6%. Losers: TCOM -9.0%. NLOK -8.3%. JCS -5.2%. GOOGL -4.8%. GNLN -4.2%. For further details see: ZBRA, FGEN, GOOGL and TCOM among after hours movers
The rising stock market had many winners on Wednesday, but alas for its shareholders FibroGen (NASDAQ: FGEN) wasn't one of them. The biotech's shares declined by over 9% following a downgrade from a famous investment bank. Goldman Sachs analyst Paul Choi has downshifted his ...
News, Short Squeeze, Breakout and More Instantly...
SAN FRANCISCO, June 18, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host the second part of its virtual KOL investor event series on Wednesday, June 26, 2024 at 10:00 AM ET. To register, click here . The event will feature Rahul Aggarwal, M.D. (Uni...
2024-06-12 09:44:18 ET USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 12, 2024 – USA News Group – After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovere...
FibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combination with LIBTAYO ® in patients with select solid tumors FibroGen to evaluate FG-3175, an anti-c-c motif chemokine receptor 8 (CCR8) mAb, a...